Axsome Therapeutics is trading 8.61% down at $132.00 as investors weigh heavy spending, higher expected fourth-quarter gross-to-net discounts and whether rapid growth can continue from a larger base. - On November 2, 2026, third-quarter revenue of $259.7 million and a loss of $0.25 per share both beat analyst expectations. - Axsome reported a $1 billion annualized revenue run rate and said cash should fund operations through cash-flow positivity. - Investing.com reported a 3.77% premarket drop; broader indexes were higher. No volume data was provided.